Advertisement FDA approves ViroPharma sNDA for Modernized Labeling of Vancocin - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

FDA approves ViroPharma sNDA for Modernized Labeling of Vancocin

ViroPharma has received US FDA approval for a supplemental new drug application (sNDA) for the modernization of labeling for Vancocin (vancomycin hydrochloride, USP) Capsules.

Following the approval for sNDA, the capsules’ labeling will feature clinical safety and efficacy data for Vancocin in treating currently circulating strains of Clostridium difficile, including the BI/NAP1 strain.

Vancocin’s label also comprises key safety and efficacy data from 260 patients with C. difficile associated diarrhea (CDAD) treated with the drug.

ViroPharma president and CEO said the new labeling allows for better understanding on how to treat and monitor patients suffering from serious infections that require oral Vancocin therapy